Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 2/20 | 0.39 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.36 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258466 | 1.00 | SSTR3 (0.39) | SSTR3GID4HRH3METTL3METTL14 | |
| SCHEMBL4264985 | 0.82 | LMNA (0.50) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4264983 | 0.82 | LMNA (0.50) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL2278489 | 0.78 | SSTR3 (0.54) | SSTR3GID4HRH3CHRNA7CASR | |
| SCHEMBL4260562 | 0.75 | CARM1 (0.45) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4260567 | 0.75 | CARM1 (0.45) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4257825 | 0.74 | MCHR1 (0.43) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4257832 | 0.74 | MCHR1 (0.43) | LMNACYP1A2CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4260890 | 0.72 | ALDH1A1 (0.52) | LMNA | |
| SCHEMBL4260882 | 0.72 | ALDH1A1 (0.52) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | SSTR3 478/4885GID4 240/4885HRH3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.